Management of Neutropenia in Patients Receiving Chemotherapy
Introduction to Neutropenia Management
- The National Comprehensive Cancer Network recommends initiating G-CSF (filgrastim 5 mcg/kg/day or pegfilgrastim 6 mg once per cycle) starting 24 hours after chemotherapy completion when the risk of febrile neutropenia is ≥20%, and immediately starting broad-spectrum antibiotics for any patient who develops fever with neutropenia 1, 2, 3
Risk Stratification and Primary Prophylaxis
- Primary prophylaxis with G-CSF is recommended when the chemotherapy regimen carries a ≥20% risk of febrile neutropenia 2, 3
- Patient-specific risk factors, such as age ≥65 years, prior febrile neutropenia, extensive prior chemotherapy, poor performance status, and advanced disease, also warrant primary prophylaxis with G-CSF 4, 2
- The subcutaneous route is preferred for all G-CSF agents, with filgrastim and pegfilgrastim being Category 1 recommendations 1
Management of Febrile Neutropenia
- When fever develops (temperature ≥38.0°C) with neutropenia, immediate actions include obtaining blood cultures and relevant cultures before antibiotics, and initiating empiric broad-spectrum antibiotics immediately 5, 6, 7
- First-line antibiotic options include levofloxacin 500 mg orally daily or ciprofloxacin 500 mg orally twice daily for outpatient/low-risk patients, and antipseudomonal beta-lactam monotherapy for inpatient/high-risk patients 7, 5
Secondary Prophylaxis
- After an episode of febrile neutropenia, G-CSF support is justified for subsequent chemotherapy cycles when maintaining dose intensity is critical for curative intent 8, 9
- However, chemotherapy dose reduction is an acceptable alternative when no survival benefit from maintaining dose intensity has been demonstrated 8, 9
Infection Prevention Measures
- Non-pharmacologic interventions include maintaining good skin integrity and oral/dental hygiene, avoiding rectal thermometers and examinations, and removing plants and flowers from patient rooms 6
- Antimicrobial prophylaxis may be considered for patients with ANC <500/mcL, including fluoroquinolone for antibacterial prophylaxis and fluconazole for antifungal prophylaxis 5
Special Populations
- For patients with acute myeloid leukemia (AML), sargramostim is specifically indicated for older adults after induction chemotherapy 1, 10
- For patients with severe chronic neutropenia, filgrastim dosing varies by condition, with 3-10 mcg/kg/day for congenital neutropenia and 5 mcg/kg/day for cyclic/idiopathic neutropenia 1